drugset / Trial / NCT00227019
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Phase 2
Completed
16 enrolled
Heather Wakelee
Eli Lilly and Company · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial evaluated the safety of combining bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) patients with stable brain metastases as second-line chemotherapy, while evaluating progression-free survival (PFS) and overall survival (OS).
Timeline
- Start
- 2006-03
- Primary completion
- 2010-11
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 4 mg | Oral |
| Background | Vitamin B12 | Other / unclassified | 1000 ug | Intramuscular |
| Background | folic acid | Small molecule | 350 ug | — |
| Background | folic acid | Small molecule | 1000 ug | — |